Members Login
Medical News Feed
EPG Search
Frequent Searches:
Browse Other Languages
Spanish Drug Data (España)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
YouTube - Featured Content
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Are you a Doctor or Healthcare Professional? Authorise Viewing
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Change language
Current language database:
United Kingdom
Drug details for : XIGRIS Solution for Infusion
| Drug class description : | Antithrombotic agents, enzymes |
| Generic Name : | Drotrecogin alfa |
| Drug description : | Powder for solution for infusion. |
| Presentation : | Each vial contains: Drotrecogin alfa (activated): 2mg per ml after reconstitution. Xigris 5mg powder for solution for infusion: A vial contains 5mg of drotrecogin alfa (activated) to be reconstituted with 2.5ml of sterile water for injection. Xigris 20mg powder for solution for infusion: A vial contains 20mg of drotrecogin alfa (activated) to be reconstituted with 10ml of sterile water for injection. Drotrecogin alfa (activated) is a recombinant version of the endogenous activated protein C and is produced by genetic engineering from an established human cell line. |
| Indications : | Xigris is indicated for the treatment of adult patients with severe sepsis with multiple organ failure when added to best standard care. The use of Xigris should be considered mainly in situations when therapy can be started within 24 hours after the onset of organ failure. |
| Adult Dosage : | Xigris should be used by experienced doctors in institutions skilled in the care of patients with severe sepsis. Treatment should be started within 48 hours, and preferably within 24 hours, of onset of the first documented sepsis-induced organ dysfunction. The recommended dose of Xigris is 24µg/kg/hr given as a continuous intravenous infusion for a total duration of 96 hours. It is recommended that Xigris be infused with an infusion pump to accurately control the infusion rate. If the infusion is interrupted for any reason, Xigris should be restarted at the 24µg/kg/hr infusion rate and continued to complete the full recommended 96 hours of dosing administration. Dose escalation or bolus doses of Xigris are not necessary to account for the interruption in the infusion. No dose adjustments are required in adult patients with severe sepsis with regard to age, gender, hepatic function (as measured by transaminase levels), or renal function. The pharmacokinetics of drotrecogin alfa (activated) have not been studied in patients with severe sepsis and pre-existing end-stage renal disease and chronic hepatic disease. |
| Child Dosage : | Data from a placebo-controlled clinical trial, which was stopped for futility after 477 patients 0 to 17 years old had received the study drug, did not establish efficacy of Xigris in paediatric patients and showed a higher rate of central nervous system bleeding in the Xigris versus placebo group. Therefore, no dosage recommendation can be made and the use of Xigris is not recommended in children below the age of 18 (See Special Precautions). |
| Elderly Dosage : | See Adult Dosage |
| Contra Indications : | Because drotrecogin alfa (activated) may increase the risk of bleeding, Xigris is contra-indicated in the following situations: • Active internal bleeding. • Patients with intracranial pathology; neoplasm or evidence of cerebral herniation. • Concurrent heparin therapy 15 international units/kg/hr. • Known bleeding diathesis except for acute coagulopathy related to sepsis. • Chronic severe hepatic disease. • Platelet count <30,000 x 106/l, even if the platelet count is increased after transfusions. • Patients at increased risk for bleeding (for example): a) Any major surgery, defined as surgery that requires general or spinal anaesthesia, performed within the 12-hour period immediately preceding drug infusion, or any postoperative patient who demonstrates evidence of active bleeding, or any patient with planned or anticipated surgery during the drug infusion period. b) History of severe head trauma that required hospitalisation, intracranial or intraspinal surgery, or haemorrhagic stroke within the previous 3 months, or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesion; patients with an epidural catheter or who are anticipated to receive an epidural catheter during drug infusion. c) History of congenital bleeding diatheses. d) Gastro-intestinal bleeding within the last 6 weeks that has required medical intervention unless definitive surgery has been performed. e) Trauma patients at increased risk of bleeding. Xigris is also contra-indicated in patients with known hypersensitivity to drotrecogin alfa (activated), to any of the formulation excipients, or to bovine thrombin (a trace residue from the manufacturing process). |
| Special Precautions : | Patients With Single Organ Dysfunction and Recent Surgery: Xigris is not approved for the treatment of patients with single organ dysfunction and should not be used in this particular subgroup of patients, especially if they had recent surgery (within 30 days). In each of two randomised, placebo-controlled trials, PROWESS and ADDRESS, 28-day and in-hospital mortality were higher in patients treated with drotrecogin alfa (activated) compared to placebo for the subpopulation of patients with single organ dysfunction and recent surgery (n = 98 in PROWESS and n = 636 in ADDRESS). Bleeding: Drotrecogin alfa (activated) increases the risk of bleeding. In the following conditions, the risks of the administration of Xigris should be weighed against the anticipated benefits: • Recent administration (within 3 days) of thrombolytic therapy. • Recent administration (within 7 days) of oral anticoagulants. • Recent administration (within 7 days) of aspirin or other platelet inhibitors. • Recent (within 3 months) ischaemic stroke. • Any other condition in which the physician considers significant bleeding is likely. For procedures with an inherent bleeding risk, discontinue Xigris for 2 hours prior to the start of the procedure. Xigris may be restarted 12 hours after major invasive procedures or surgery if adequate haemostasis has been achieved. Xigris may be restarted immediately after uncomplicated less invasive procedures if adequate haemostasis has been achieved. As a component of routine care, measures of haemostasis (eg, activated partial thromboplastin time [APTT], prothrombin time [PT], and platelet count) should be obtained during the infusion of Xigris. If sequential tests of haemostasis indicate an uncontrolled or worsening coagulopathy that significantly increases the risk of bleeding, the benefits of continuing the infusion must be weighed against the potential increased risk of bleeding for that patient. Laboratory Tests: Drotrecogin alfa (activated) has minimal effect on the PT. Prolongation of the APTT in patients with severe sepsis receiving Xigris may be due to the underlying coagulopathy, the pharmacodynamic effect of drotrecogin alfa (activated), and/or the effect of other concurrent medications. The pharmacodynamic effect of drotrecogin alfa (activated) on the APTT assay is dependent on the reagent and instrument used to perform the assay and the time that elapses between sample acquisition and assay performance. Drotrecogin alfa (activated) that is present in a blood or plasma sample drawn from a patient who is being infused with the drug will be gradually neutralised by endogenous plasma protease inhibitors present in the sample. Virtually no measurable activity of drotrecogin alfa (activated) is present 2 hours after obtaining the blood sample. Due to these biological and analytical variables, the APTT should not be used to assess the pharmacodynamic effect of drotrecogin alfa (activated). In addition, approximately 2 hours after terminating the infusion of the drug, there is virtually no measurable activity of drotrecogin alfa (activated) remaining in the circulation of the patient; blood samples drawn for APTT determination after this point are no longer affected by the drug. The interpretation of sequential determinations of the PT and/or APTT should take these variables into consideration. Because drotrecogin alfa (activated) may affect the APTT assays, drotrecogin alfa (activated) present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as Factor VIII, IX, and XI assays). Drotrecogin alfa (activated) present in plasma samples does not interfere with one-stage factor assays based on the PT (such as Factor II, V, VII, and X assays). If sequential measures of coagulopathy (including platelet count) indicate severe or worsening coagulopathy, the risk of continuing the infusion should be weighed against the expected benefit. Immunogenicity: In patients with severe sepsis, the formation of anti-activated protein C antibodies was uncommon (<1%) after a single course of therapy. These antibodies were not capable of neutralising the effect of activated protein C on the APTT assay. However, the possibility of allergic reactions to constituents of the preparation cannot be completely excluded in certain predisposed patients. If allergic or anaphylactic reactions occur, treatment should be discontinued immediately and appropriate therapy initiated. Xigris has not been re-administered to patients with severe sepsis. If Xigris is re-administered to patients, caution should be employed. No anti-activated protein C antibody formation was detected in healthy subjects, even after repeat administration. Paediatric Patients: Xigris is not recommended in children below the age of 18 and therefore it should not be used in children. Data from a placebo-controlled clinical trial did not establish efficacy of Xigris in paediatric patients suffering from severe sepsis, acute infection, systemic inflammation, and respiratory and cardiovascular organ dysfunction. This trial was stopped for futility after 477 patients had received the study drug (out of 600 patients intended). A planned interim analysis (with 400 patients enrolled) showed a low likelihood of demonstrating a significant difference in the primary endpoint of “Composite Time to Complete Organ Failure Resolution” (CTCOFR score of 9.8 versus 9.7 mean days over 14 days). There was also no difference in 28-day mortality (17.1% versus 17.3% in the Xigris and placebo groups, respectively). Investigators attributed 2 deaths in the Xigris group and 5 deaths in the placebo group to bleeding events. There was a higher rate of central nervous system (CNS) bleeding in the drotrecogin alfa (activated) versus the placebo group. Over the infusion period (study days 0-6) the number of patients experiencing CNS bleeding was 5 versus 1 (2.1% versus 0.4%) for the overall population (drotrecogin alfa [activated] versus placebo), with 4 of the 5 events in the drotrecogin alfa (activated) group occurring in patients 60 days old or 3.5 kg bodyweight. Fatal CNS bleeding events, serious bleeding events (over the infusion period and over the 28-day study period), serious adverse events, and major amputations were similar in the drotrecogin alfa (activated) and placebo groups. |
| Interactions : | Drug interactions with Xigris have not been studied in patients with sepsis. Caution should be employed when Xigris is used with other drugs that affect haemostasis (See Contraindications and Special Precautions), including protein C, thrombolytics (eg, streptokinase, tPA, rPA, and urokinase), oral anticoagulants (eg, warfarin), hirudins, antithrombin, aspirin, and other anti-platelets agents, eg, non-steroidal anti-inflammatory drugs, ticlopidine and clopidogrel, glycoprotein IIb/IIIa antagonists (such as abciximab, eptifibatide, tirofiban), and prostacyclins, such as iloprost. Heparin: Two-thirds of patients in the Phase 3 trial received prophylactic doses of unfractionated or low molecular weight heparin. There was no observed increase in the risk of bleeding events reported as serious adverse events in drotrecogin alfa (activated) patients receiving heparin. The effects of prophylactic low dose heparin and other coagulation-active medications on the efficacy of drotrecogin alfa (activated) have not been evaluated in a randomised controlled clinical trial. Pregnancy and lactation: Animal studies with respect to effects on pregnancy, embryonal/foetal development, parturition, and postnatal development have not been conducted with Xigris. Therefore, the potential risk for humans is unknown. Xigris should not be used during pregnancy unless clearly necessary. It is not known whether Xigris is excreted in human milk or if there is a potential effect on the nursed infant. Therefore, the patient should not breast-feed whilst treated with Xigris. |
| Adverse Reactions : | Xigris increases the risk of bleeding. The Phase 3, international, multi-centre, randomised, double-blind, placebo-controlled clinical trial (PROWESS) involved 850 drotrecogin alfa (activated)-treated and 840 placebo-treated patients. The percentage of patients experiencing at least one bleeding event in the two treatment groups was 24.9% and 17.7%, respectively. In both treatment groups, the majority of bleeding events were ecchymosis or gastro-intestinal tract bleeding. The difference in the incidence of serious bleeding events between the two treatment groups occurred primarily during study drug administration. A total of 2,378 adult patients with severe sepsis received drotrecogin alfa (activated) in a Phase 3b, international, single-arm, open-label clinical trial (ENHANCE). The incidence of serious bleeding events in the PROWESS and ENHANCE studies is provided below. In these studies, serious bleeding events included any intracranial haemorrhage, any life-threatening or fatal bleed, any bleeding event requiring the administration of 3 units of packed red blood cells per day for 2 consecutive days, or any bleeding event assessed as serious by the investigator. A Phase 3b, international, multi-centre, randomised, double-blind, placebo-controlled clinical trial (ADDRESS) of adult severe sepsis patients at low risk of death involved 1,317 drotrecogin alfa (activated)-treated and 1,293 placebo-treated patients. The percentage of patients experiencing at least one bleeding event in the two treatment groups was 10.9% and 6.4%, respectively (P <0.001). Bleeding events included serious bleeding events, bleeding events assessed as possibly study drug related by the investigator, bleeding events associated with the need for a red blood cell transfusion, and bleeding events that led to permanent discontinuation of the study drug. In the ADDRESS trial, serious bleeding events included any fatal bleed, any life-threatening bleed, any CNS bleed, or any bleeding event assessed as serious by the investigator. Serious Bleeding Events During the Infusion Period In ADDRESS, the percent of treated patients experiencing a serious bleeding event by site of haemorrhage was similar to that observed in PROWESS. The incidence of serious bleeding events during infusion (defined as study day 0 through study day 6) was 31 (2.4%) and 15 (1.2%) in drotrecogin alfa (activated)-treated and placebo-treated patients, respectively (P = 0.02). The incidence of CNS bleeds during infusion was 4 (0.3%) and 3 (0.2%) for drotrecogin alfa (activated)-treated and placebo-treated patients, respectively. Recent surgery (within 30 days prior to study entry) was associated with a numerically higher risk of serious bleeding during infusion in both the Xigris-treated and the placebo-treated patients (Xigris: 3.6% in patients with recent surgery versus 1.6% in patients without recent surgery; placebo: 1.6% versus 0.9%, respectively). Serious Bleeding Events During the 28-Day Study Period In PROWESS, the incidence of serious bleeding events during the 28-day study period was 3.5% and 2.0% in drotrecogin alfa (activated)-treated and placebo-treated patients, respectively. The incidence of CNS bleeds during the 28-day study period was 0.2% and 0.1% for drotrecogin alfa (activated)-treated and placebo-treated patients, respectively. The risk of CNS bleeding may increase with severe coagulopathy and severe thrombocytopenia (See Contraindications and Special Precautions). In the open-label ENHANCE study, the incidence of serious bleeding events during the 28-day study period was 6.5%, and the incidence of CNS bleeds during the 28-day study period was 1.5%. In the placebo-controlled ADDRESS study, the incidence of serious bleeding events during the 28-day study period was 51 (3.9%) and 28 (2.2%) in drotrecogin alfa (activated)-treated and placebo-treated patients, respectively (P = 0.01). The incidence of CNS bleeds during the 28-day study period was 6 (0.5%) and 5 (0.4%) for drotrecogin alfa (activated)-treated and placebo-treated patients, respectively. In the Phase 1 studies, adverse events with a frequency of 5% included headache (30.9%), ecchymosis (23.0%), and pain (5.8%). |
| Manufacturer : | Eli Lilly |
| Drug Availability : | (POM) |
Free registration to access disease diagnosis, patient management, physician tools.
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org